Peyronel Francesco, Della-Torre Emanuel, Maritati Federica, Urban Maria L, Bajema Ingeborg, Schleinitz Nicolas, Vaglio Augusto
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Nat Rev Rheumatol. 2025 May;21(5):275-290. doi: 10.1038/s41584-025-01240-x. Epub 2025 Apr 7.
IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder usually characterized by multi-organ involvement. Its pathogenesis is complex and involves genetic and environmental factors, while immune responses usually mediate organ damage and promote fibrosis, which is a key feature of the disease. IgG4 responses, however, are not exclusive to IgG4-RD and can be encountered in other diseases with phenotypes that partially overlap that of IgG4-RD. Although IgG4-RD has clinical and histological hallmarks, the lack of validated diagnostic criteria often makes the diagnosis challenging, requiring a multi-dimensional approach that integrates clinical, radiological and serological data. The present Review covers recent advances in the understanding of disease drivers and its clinical phenotypes, mainly focusing on the differential diagnosis with potential IgG4-RD mimickers, namely histiocytoses, lymphoproliferative disorders, systemic vasculitides and other immune-mediated conditions. The Review also provides a schematic approach to IgG4-RD treatment, including a brief overview of glucocorticoid-sparing agents and emerging therapies, from B cell-depleting monoclonal antibodies to cytokine-targeting drugs, the majority of which are currently under investigation in randomized clinical trials.
IgG4相关疾病(IgG4-RD)是一种纤维炎症性疾病,通常以多器官受累为特征。其发病机制复杂,涉及遗传和环境因素,而免疫反应通常介导器官损伤并促进纤维化,这是该疾病的一个关键特征。然而,IgG4反应并非IgG4-RD所特有,在其他具有部分重叠于IgG4-RD表型的疾病中也可出现。尽管IgG4-RD具有临床和组织学特征,但缺乏经过验证的诊断标准常常使诊断具有挑战性,需要一种整合临床、放射学和血清学数据的多维度方法。本综述涵盖了在疾病驱动因素及其临床表型理解方面的最新进展,主要聚焦于与潜在的IgG4-RD模仿者(即组织细胞增多症、淋巴增殖性疾病、系统性血管炎和其他免疫介导的疾病)的鉴别诊断。该综述还提供了一种IgG4-RD治疗的示意性方法,包括对糖皮质激素节省剂和新兴疗法的简要概述,从耗竭B细胞的单克隆抗体到靶向细胞因子的药物,其中大多数目前正在随机临床试验中进行研究。